P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec®), a second-generation non-sedating antihistamine

Journal of Pharmaceutical Sciences

Volumn 92, Issue 10, 2003, Pages 2082-2089

  Polli, Joseph W ^a   Baughman, Todd M ^a   Humphreys, Joan E ^a   Jordan, Kelly H ^a   Mote, Angela L ^a   Salisbury, Jo A ^a   Tippin, Timothy K ^a   Serabjit Singh, Cosette J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antihistamines; Drug interaction; Efflux transporter; In vivo, blood brain barrier; Knockout mice; P glycoprotein; Sedation

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; ELACRIDAR; GLYCOPROTEIN P; GW 823739X; HYDROXYZINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SEDATION;

EID: 0141507948     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10453     Document Type: Article

References (18)

1. PDR Electronic Library™ Online. 2002. Greenwood Village, CO: Thomson MICROMEDEX.
2. Agrawal DK. 2002. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs 10:547-560.
3. Simons FER, Simons KJ. 1994. The pharmacology and use of H1-receptor antagonist drugs. N Engl J Med 330:1663-1670.
4. Handley DA, Magnetti A, Higgins AJ. 1998. Therapeutic advantages of third generation antihistamines. Expert Opin Investig Drugs 7:1045-1054.
5. Snowman AM, Snyder SH. 1990. Cetirizine: Actions on neurotransmitter receptors. J Allergy Clin Immunol 86:1025-1028.
6. Lin JH, Yamazaki M. 2003. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet 4:59-98.
7. Hagenbuch B, Gao B, Meier PJ. 2002. Transport of xenobiotics across the blood-brain barrier. News Physiol Sci 17:231-234.
8. Chishty M, Reichel A, Siva J, Abbott NJ, 2001. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target 9:223-228.
9. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. 2002. Passive permeability and P-glycoprotein mediated efflux differentiate CNS and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
10. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CJ. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
11. Lenegre A, Avril I, Fromage S, Milinkevitch D, Porsolt RD. 1988. Absence of amnesia induction in mice with hydroxyzine in comparison with three other minor tranquillizers. Arzneimittelforschung 38:558-560.
12. Kalvass JC, Maurer TS. 2002. Influence of non-specific brain and plasma binding on CNS exposures: Implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
13. Timmerman H. 1999. Why are non-sedating antihistamines non-sedating? Clin Exp Allergy 29:13-18.
14. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
15. Hagenbuch B, Meier PJ. 2003. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18.
16. Chen C, Hanson E, Watson JW, Lee JS. 2003. P-glycoprotein limits the brain penetration of non-sedating but not sedating H1-antagonist. Drug Metab Dispos 31:312-318.
17. Schwab M, Eichelbaum M, Fromm MF. 2003. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmcol Toxicol 43:285-307.
18. Clark DE. 1999. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. I. Prediction of intestinal absorption. J Pharm Sci 88:807-814.